Switch to biosimilars in hemodialysis patients: Efficacy, safety and cost analysis in a single centre;Lo switch a biosimilari dell'eritropoietina alfa in emodialisi: Analisi dell'efficacia, della sicurezza e dei costi in un singolo centro

Ricerca e Pratica

Volumn 33, Issue 1, 2017, Pages 5-12

  Morosetti, Massimo ^a   Dominijanni, Sara ^a   Calzona, Anna Bianca ^b   Zappalà, Laura ^a   Nicolais, Rebeca ^a   Di Turi, Roberta ^b  

^a Ospedale GB Grassi   (Italy)

^b Roma3 University   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BIOSIMILAR AGENT; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

AGED; ARTICLE; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SCREENING; HEALTH CARE COST; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PATIENT SAFETY; THROMBOSIS; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE;

EID: 85016318015     PISSN: 1120379X     EISSN: 20382480     Source Type: Journal    
DOI: None     Document Type: Article

References (0)